SCHEMBL2765541

SCHEMBL2765541

Cc1ccc(-c2cc(C)n(C(n3nc(-c4ccc(C)cc4)cc3C)n3nc(-c4ccc(C)cc4)cc3C)n2)cc1.Cl[Mn]Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.44
NPC1 O15118 7/20 0.44
RAB9A P51151 7/20 0.44
ALDH1A1 P00352 6/20 0.44
KDM4E B2RXH2 5/20 0.44
MAPT P10636 8/20 0.41
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
TP53 P04637 3/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
PTGS2 P35354 4/20 0.40
LMNA P02545 4/20 0.40
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2454595 0.93 SMN1; SMN2 (0.49) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL2766524 0.87 RAB9A (0.44) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL2458919 0.79 RAB9A (0.49) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL2454381 0.77 DYRK1A (0.39) SMN1; SMN2NPC1RAB9AKDM4EMAPT
SCHEMBL2765958 0.75 SMN1; SMN2 (0.43) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL14996561 0.71 NPC1 (0.50) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL2765018 0.71 SMN1; SMN2 (0.39) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
Butadiene SCHEMBL2766054 0.71 RAB9A (0.42) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL14996633 0.71 SMN1; SMN2 (0.51) SMN1; SMN2NPC1RAB9AALDH1A1KDM4E
SCHEMBL2460517 0.69 CYP2A6 (0.53) ALDH1A1KDM4EMAPTCYP2C19CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1266911-B1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL CO (JP) 2010-04-14 EP disclosed
US-6881802-B2 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-04-19 US disclosed
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2003-02-13 US disclosed
EP-1266911-A1 Catalyst for addition polymerization and process for producing an addition polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-12-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030032743-A1 Catalyst for addition polymerization and process for producing an addition polymer BRAP, MCM4, BOLA2; BOLA2B SMN1; SMN2 3048/4885NPC1 3681/4885RAB9A 3554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.